Section Edited by Aude Chapuis, MD and Marcela V. Maus, MD, PhD
Immune cell therapies and cell engineering approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, synthetic gene circuits. Includes pre-clinical animal modeling (small and large) and clinical trials.
IL-12-producing cytokine factories induce precursor exhausted T cells and elimination of primary and metastatic tumorsAmanda Nash, Jonathon DeBonis, Danna Murungi, Bertha Castillo, Boram Kim, Fangheng Hu, Courtney Chambers, Annie Nguyen, Andrea Hernandez, Zeshi Wang, Peter D Rios, Sofia Ghani, Ira Joshi, Douglas Isa, Ningbo ZhengSee the full list of authors
1 April 2025
Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myelomaChunxiang Jin, Rongrong Chen, Shan Fu, Mingming Zhang, Yuanyin Teng, Tingting Yang, Fengmei Song, Jingjing Feng, Ruimin Hong, Jiazhen Cui, Simao Huang, Huijun Xu, Yanlei Zhang, Guoqing Wei, Zhen CaiSee the full list of authors
28 March 2025
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodiesJulien Montorfani, Eric Hatterer, Laurence Chatel, Adeline Lesnier, Alizée Viandier, Bruno Daubeuf, Lise Nouveau, Pauline Malinge, Sebastien Calloud, Krzysztof Masternak, Walter Ferlin, Nicolas Fischer, Camilla Jandus, Limin Shang
25 March 2025
Leucine-rich α-2 glycoprotein 1 (LRG1) during inflammatory complications after allogeneic stem cell transplantation and CAR-T cell therapySarah Mertlitz, Katarina Riesner, Martina Kalupa, Nora Uhlig, Steffen Cordes, Lydia Verlaat, Mina Jamali, Ningyu Li, Hadeer Mohamed Elsayed Rasheed Mohamed, Lars Bullinger, Stephen Moss, John Greenwood, Jerome Jatzlau, Petra Knaus, Pedro Vallecillo-GarciaSee the full list of authors
21 March 2025
Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancersAurelie Drouin, Laurine Durand, Clara Esnault, Pauline Gaboriaud, Valérie Leblond, Shawk Karim, Morgane Fouché, Christine Dhommée, Christine B Baltus, Fanny Boursin, Nicolas Aubrey, Roland Houben, David Schrama, Serge Guyétant, Audrey DesgrangesSee the full list of authors
13 March 2025
Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engagerParis Kosti, Johan Abram-Saliba, Laetitia Pericou-Troquier, Sarah Pavelot, Tiphaine Ruggeri, Marc Laffaille, Melita Irving, George Coukos, Evripidis Lanitis, Steven M. Dunn
13 March 2025
Boosting tumor homing of endogenous natural killer cells via therapeutic secretomes of chemically primed natural killer cellsSeohyun Cho, Seung Hee Choi, Eunchong Maeng, Hail Park, Ki Seo Ryu, Kyung-Soon Park
5 March 2025
Tumor-specific CD8 T cells from the bone marrow resist exhaustion and exhibit increased persistence in tumor-bearing hosts as compared with tumor-infiltrating lymphocytesElizabeth M Zawidzka, Luca Biavati, Amy Thomas, Claudio Zanettini, Luigi Marchionni, Robert Leone, Ivan Borrello
25 February 2025
Phosphatidylserine as a tumor target for CAR-T cell therapyCelia Martín-Otal, Inés Sánchez-Moreno, Alvaro Gómez-Morón, Carla Castro, Noelia Casares, Flor Navarro, Marta Gorraiz, Pedro Justicia-Lirio, Felix Pareja, María Collantes, Iván Peñuelas, Mercedes Iñarrairaegui, Bruno Sangro, Isabel Vivas, Marta LarrayozSee the full list of authors
23 February 2025
Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastomaKhloe S Gordon, Caleb R Perez, Andrea Garmilla, Maxine S Y Lam, Joey J Y Aw, Anisha Datta, Douglas A Lauffenburger, Andrea Pavesi, Michael E Birnbaum
11 February 2025